Table 1.
Clinicopathological characteristics of the discovery and COEUR cohorts.
| Values (%) | |||
|---|---|---|---|
| Variables | Discovery | COEUR | |
| Number of patients | Total | 101 | 1158 |
| Age of patients at diagnosis | Median (years) | 61.0 | 62.0 |
| Range (years) | 34–81 | 26–91 | |
| Ovarian cancer histotype * | High grade serous | 101 (100.0) | 1093 (94.4) |
| Low grade serous | / | 31 (2.7) | |
| Endometrioid | / | 14 (1.2) | |
| Clear cell | / | 9 (0.8) | |
| Mucinous | / | 2 (0.2) | |
| Unknown | / | 9 (0.8) | |
| BRCA1/2 status | Wild-type | / | 339 (29.3) |
| BRCA1 mutation | / | 53 (4.5) | |
| BRCA2 mutation | / | 22 (1.9) | |
| BRCA1/2 mutationsc | / | 3 (0.3) | |
| Unknown | / | 741 (64.0) | |
| Stage (FIGO) | 1 | 4 (4.0) | 77 (6.7) |
| 2 | 7 (6.9) | 124 (10.7) | |
| 3 | 72 (71.3) | 801 (69.2) | |
| 4 | 12 (11.9) | 108 (9.30) | |
| Unknown | 6 (5.9) | 48 (4.10) | |
| Residual disease | No residual disease | 18 (17.8) | 206 (17.8) |
| Yes, size not specified | 7 (6.9) | 155 (13.4) | |
| ≤1 cm | 20 (19.8) | 224 (19.3) | |
| 1 cm–≤2 cm | 22 (21.8) | 81 (7.0) | |
| 2 cm | 26 (25.7) | 171 (14.8) | |
| Miliary | 3 (3.0) | 34 (2.9) | |
| Unknown | 5 (5.0) | 287 (24.8) | |
| Chemotherapy before surgery * | No | 98 (97.0) | 1093 (94.4) |
| Yes | 3 (3.0) | 65 (5.6) | |
| First line chemotherapy | Platinum b + taxol | 76 (75.2) | 901 (77.8) |
| Platinum b | 2 (2.0) | 59 (5.1) | |
| Taxol | 2 (2.0) | 3 (0.3) | |
| Others | 21 (20.8) | 98 (8.5) | |
| None | / | 22 (1.9) | |
| Unknown | / | 75 (6.5) | |
| Overall survival time | Median (months) | 48.0 | 36.1 |
| Range (months) | 3–202 | 0–202 | |
| Progression free survival time | Median (months) | 18.0 | 15.0 |
| Range (months) | 1–202 | 0–195 | |
* Patients with histopathology other than HGSC and patients with neoadjuvant chemotherapy were excluded from the analysis. a Number of years between sample collection and study. b Platinum includes cisplatin and/or carboplatin. c Patients with mutations on BRCA1 and BRCA2 genes.